FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999036638> ?p ?o ?g. }

• W2999036638 abstract "ABSTRACT Background Rarioimmunotherapy (RIT) with 90-yttrium ibritumomab tiuxetan (90Y-IT) is known to be an effective approach for treatment of NHL, because lymphoma is highly radiosensitive, however, 3-year progression-free survival in our department is 39.1% (overall survival is 79.9%), which is not sufficient considering the cost-effectiveness. Consolidation therapy with RIT is another attractive approach; however, bone marrow suppression is a major and life-threatening issue for especially aged patients. In view of these findings, we employed RIT (90Y-IT) followed by HDT (LEED) in patients with relapsed and refractory B-cell lymphoma. In this report, we tried to evaluate the safety and efficacy of RIT using ibritumomab tiuxetan (Zevalin) combined with high-dose LEED chemotherapy and ASCT (Z-LEED) in refractory/relapsed B-cell lymphoma. Patients and methods Eight patients with relapsed or refractory B-cell lymphoma (three mantle cell lymphoma patients and five grade III FL/DLBCL patients) were treated with Z-LEED. After PBSC mobilization and harvesting, the minimum target dose of CD34+ cells (2 × 106/kg) was stored. Patients were 111In ibritumobab tiuxetan (185 MBq IV) on day 1, followed by 90Y-IT (14.8 MBq/kg IV] administration on day 8 after rituximab. Then high-dose chemotherapy was delivered using the LEED (500 mg/m2 etoposide on day 4, 3, and 2; 60 mg/m2 cyclophosphamide on day 4 and 3; 130 mg/m2 mephalan on day 1; and 40 mg/m2 dexamethasone on day 4, 3, 2 and 1). Results Two patients had received more than three prior treatments, and three had chemotherapy-resistant disease. There were no therapy-related deaths. While one patient with conventionally measurable disease at the time of treatment, the respective complete and overall response rates were 100%. Seven patients remain CR at 2–27 months from transplantation and 8–102 months from diagnosis. One patient relapsed after 4 months from transplantation. Conclusion ibritumomab tiuxetan combined with LEED high-dose chemotherapy is safe and possibly effective as a conditioning regimen for ASCT." @default.
• W2999036638 created "2020-01-23" @default.
• W2999036638 creator A5004550999 @default.
• W2999036638 creator A5008356450 @default.
• W2999036638 creator A5019950332 @default.
• W2999036638 creator A5026293332 @default.
• W2999036638 creator A5035811684 @default.
• W2999036638 creator A5045468227 @default.
• W2999036638 creator A5046848689 @default.
• W2999036638 creator A5047678196 @default.
• W2999036638 creator A5068376268 @default.
• W2999036638 creator A5070676345 @default.
• W2999036638 creator A5072464786 @default.
• W2999036638 creator A5091073871 @default.
• W2999036638 date "2012-10-01" @default.
• W2999036638 modified "2023-09-26" @default.
• W2999036638 title "Clinical Outcome of Radioimmunotherapy with ASCT (Z-Leed) for Relapsed and Refractory B-Cell Lymphoma" @default.
• W2999036638 doi "https://doi.org/10.1016/s0923-7534(20)32280-8" @default.
• W2999036638 hasPublicationYear "2012" @default.
• W2999036638 type Work @default.
• W2999036638 sameAs 2999036638 @default.
• W2999036638 citedByCount "0" @default.
• W2999036638 crossrefType "journal-article" @default.
• W2999036638 hasAuthorship W2999036638A5004550999 @default.
• W2999036638 hasAuthorship W2999036638A5008356450 @default.
• W2999036638 hasAuthorship W2999036638A5019950332 @default.
• W2999036638 hasAuthorship W2999036638A5026293332 @default.
• W2999036638 hasAuthorship W2999036638A5035811684 @default.
• W2999036638 hasAuthorship W2999036638A5045468227 @default.
• W2999036638 hasAuthorship W2999036638A5046848689 @default.
• W2999036638 hasAuthorship W2999036638A5047678196 @default.
• W2999036638 hasAuthorship W2999036638A5068376268 @default.
• W2999036638 hasAuthorship W2999036638A5070676345 @default.
• W2999036638 hasAuthorship W2999036638A5072464786 @default.
• W2999036638 hasAuthorship W2999036638A5091073871 @default.
• W2999036638 hasBestOaLocation W29990366381 @default.
• W2999036638 hasConcept C121332964 @default.
• W2999036638 hasConcept C126322002 @default.
• W2999036638 hasConcept C142424586 @default.
• W2999036638 hasConcept C143998085 @default.
• W2999036638 hasConcept C159654299 @default.
• W2999036638 hasConcept C203014093 @default.
• W2999036638 hasConcept C2776146153 @default.
• W2999036638 hasConcept C2776694085 @default.
• W2999036638 hasConcept C2776755627 @default.
• W2999036638 hasConcept C2777525834 @default.
• W2999036638 hasConcept C2778119113 @default.
• W2999036638 hasConcept C2778476748 @default.
• W2999036638 hasConcept C2778515704 @default.
• W2999036638 hasConcept C2779338263 @default.
• W2999036638 hasConcept C2780653079 @default.
• W2999036638 hasConcept C2989005 @default.
• W2999036638 hasConcept C542903549 @default.
• W2999036638 hasConcept C71924100 @default.
• W2999036638 hasConcept C87355193 @default.
• W2999036638 hasConceptScore W2999036638C121332964 @default.
• W2999036638 hasConceptScore W2999036638C126322002 @default.
• W2999036638 hasConceptScore W2999036638C142424586 @default.
• W2999036638 hasConceptScore W2999036638C143998085 @default.
• W2999036638 hasConceptScore W2999036638C159654299 @default.
• W2999036638 hasConceptScore W2999036638C203014093 @default.
• W2999036638 hasConceptScore W2999036638C2776146153 @default.
• W2999036638 hasConceptScore W2999036638C2776694085 @default.
• W2999036638 hasConceptScore W2999036638C2776755627 @default.
• W2999036638 hasConceptScore W2999036638C2777525834 @default.
• W2999036638 hasConceptScore W2999036638C2778119113 @default.
• W2999036638 hasConceptScore W2999036638C2778476748 @default.
• W2999036638 hasConceptScore W2999036638C2778515704 @default.
• W2999036638 hasConceptScore W2999036638C2779338263 @default.
• W2999036638 hasConceptScore W2999036638C2780653079 @default.
• W2999036638 hasConceptScore W2999036638C2989005 @default.
• W2999036638 hasConceptScore W2999036638C542903549 @default.
• W2999036638 hasConceptScore W2999036638C71924100 @default.
• W2999036638 hasConceptScore W2999036638C87355193 @default.
• W2999036638 hasLocation W29990366381 @default.
• W2999036638 hasOpenAccess W2999036638 @default.
• W2999036638 hasPrimaryLocation W29990366381 @default.
• W2999036638 hasRelatedWork W1736519765 @default.
• W2999036638 hasRelatedWork W2004938812 @default.
• W2999036638 hasRelatedWork W2009581882 @default.
• W2999036638 hasRelatedWork W2039021803 @default.
• W2999036638 hasRelatedWork W2048483756 @default.
• W2999036638 hasRelatedWork W2286483064 @default.
• W2999036638 hasRelatedWork W2522945448 @default.
• W2999036638 hasRelatedWork W2534414659 @default.
• W2999036638 hasRelatedWork W2554633132 @default.
• W2999036638 hasRelatedWork W2556868553 @default.
• W2999036638 hasRelatedWork W2558956640 @default.
• W2999036638 hasRelatedWork W2560229061 @default.
• W2999036638 hasRelatedWork W2563084408 @default.
• W2999036638 hasRelatedWork W2565433080 @default.
• W2999036638 hasRelatedWork W2588576916 @default.
• W2999036638 hasRelatedWork W2599885625 @default.
• W2999036638 hasRelatedWork W2603119644 @default.
• W2999036638 hasRelatedWork W295634324 @default.
• W2999036638 hasRelatedWork W2961732480 @default.
• W2999036638 hasRelatedWork W2977508402 @default.
• W2999036638 isParatext "false" @default.
• W2999036638 isRetracted "false" @default.
• W2999036638 magId "2999036638" @default.

• next